HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cinnamic acid based thiazolidinediones inhibit human P450c17 and 3beta-hydroxysteroid dehydrogenase and improve insulin sensitivity independent of PPARgamma agonist activity.

Abstract
Thiazolidinediones improve insulin sensitivity in type 2 diabetes mellitus by acting as peroxisome proliferator-associated receptor gamma (PPARgamma) agonists, and decrease circulating androgen concentrations in polycystic ovary syndrome by unknown mechanisms. Some thiazolidinediones directly inhibit the steroidogenic enzymes P450c17 and 3beta-hydroxysteroid dehydrogenase type II (3betaHSDII) by distinct mechanisms. We synthesized five novel thiazolidinediones, CLX-M1 to -M5 by linking a 2,4-thiazolidinedione moiety to a substituted alpha-phenyl cinnamic acid previously shown to have glucose-lowering effects. Using yeast microsomes expressing human P450c17 and 3betaHSDII we found that cinnamic acid methyl esters with a double bond in the thiazolidinedione core structure (M3, M5) were stronger inhibitors of P450c17 than methyl esters with the conventional core (M1, M4). These four compounds inhibited 3betaHSDII equally well, while the free cinnamic acid analog (M2) did not inhibit either enzyme. Thus, the inhibition of P450c17 and 3betaHSDII by these novel thiazolidinediones reveals structure-activity relationships independent of PPARgamma transactivation. PPARgamma transactivation was moderate (M1), weak (M2, M3) or even absent (M4, M5). While the PPARgamma agonist activity of M1 was only 3% of that of rosiglitazone, both increased glucose uptake by 3T3-L1 adipocytes and reduced serum glucose levels in ob/ob and db/db mice to a similar extent. The similar glucose-lowering effects of M1 and rosiglitazone, despite their vast differences in PPARgamma agonist activity, suggests these two actions may occur by separate mechanisms.
AuthorsWeibke Arlt, Partha Neogi, Coleman Gross, Walter L Miller
JournalJournal of molecular endocrinology (J Mol Endocrinol) Vol. 32 Issue 2 Pg. 425-36 (Apr 2004) ISSN: 0952-5041 [Print] England
PMID15072549 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Cinnamates
  • Enzyme Inhibitors
  • Hypoglycemic Agents
  • Insulin
  • PPAR gamma
  • Thiazolidinediones
  • cinnamic acid
  • 2,4-thiazolidinedione
  • 17-Hydroxysteroid Dehydrogenases
  • 3 (or 17)-beta-hydroxysteroid dehydrogenase
  • Steroid 17-alpha-Hydroxylase
  • Glucose
Topics
  • 17-Hydroxysteroid Dehydrogenases (antagonists & inhibitors)
  • 3T3 Cells (drug effects)
  • Animals
  • Cells, Cultured
  • Cinnamates (chemistry)
  • Diabetes Mellitus, Type 2 (drug therapy)
  • Drug Evaluation, Preclinical (methods)
  • Enzyme Inhibitors (chemistry, pharmacology)
  • Glucose (metabolism)
  • Humans
  • Hypoglycemic Agents (chemistry, pharmacology)
  • Insulin (pharmacology)
  • Male
  • Mice
  • Mice, Inbred Strains
  • PPAR gamma (agonists)
  • Steroid 17-alpha-Hydroxylase (antagonists & inhibitors)
  • Structure-Activity Relationship
  • Thiazolidinediones (chemistry, pharmacology)
  • Transcriptional Activation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: